Anti-Interleukin-17 Therapy of Severe Psoriatic Patients Results in an Improvement of Serum Lipid and Inflammatory Parameters’ Levels, but Has No Effect on Body Composition Parameters
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Design
2.2. Dosing Regimen of Anti-IL-17 Therapies
2.3. Evaluation of Data
3. Results
3.1. Patients’ Characteristics
3.2. Clinical and Laboratory Findings
3.3. Body-Composition Analyses
3.4. Comparing Body Composition and Laboratory Parameters between Subgroups of Patients Treated with Secukinumab or Ixekizumab
3.5. Comparing Body-Composition Parameters between Subgroups of Patients Previously Treated with Anti-TNF or Ustekinumab Therapy
3.6. Correlation Analysis of Clinical, Body-Composition, and Laboratory Parameters
4. Discussion
5. Conclusions
6. Study Limitations
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
Abbreviations
Th | T helper |
TNF | tumour necrosis factor |
IFN-γ | interferon gamma |
IL | interleukin |
BMI | body mass index |
HDL-cholesterol | high-density lipoprotein-cholesterol |
BFM | body fat mass |
FFM | fat-free mass |
SMM | skeletal muscle mass |
TBW | total body water |
ICW | intracellular water |
ECW | extracellular water |
BCM | body cell mass |
FFMI | fat-free mass index |
BFMI | body fat mass index |
SMMI | skeletal muscle mass index |
BIA | bioelectrical impedance analyzer |
PA | phase angle |
LDL-cholesterol | low-density lipoprotein-cholesterol |
ALT | alanine aminotransferase |
AST | aspartate aminotransferase |
GGT | gamma glutamyl transferase |
CRP | c-reactive protein |
ESR | erythrocyte sedimentation rate |
PASI | psoriasis area severity index |
DLQI | dermatology life-quality index |
HbA1c% | haemoglobin A1c% |
BFP | body fat percent |
IQR | interquartile ranges |
MTX | methotrexate |
FTO gene rs9939609 | alpha-ketoglutarate-dependent dioxygenase gene rs9939609 variant |
NAFLD | non-alcholic fatty liver disease |
IL-17R | interleukin-17 receptor |
LPS | lipopolysaccharide |
CCL | CC chemokine ligand |
mAb | monoclonal antibody |
VOYAGE 1 study | A study of guselkumab in the treatment of participants with moderate to severe plaque-type psoriasis |
VOYAGE 2 study | A study of guselkumab in the treatment of participants with moderate to severe plaque-type psoriasis with randomized withdrawal and retreatment |
UltIMMA-1 study | BI 655066 (risankizumab) compared to placebo and active comparator (ustekinumab) in patients with moderate to severe chronic plaque psoriasis |
UltIMMA-2 study | BI 655066 versus placebo and active comparator (ustekinumab) in patients with moderate to severe chronic plaque psoriasis |
FIXTURE | Safety and efficacy of secukinumab compared to etanercept in subjects With moderate to severe, chronic, plaque-type psoriasis |
ERASURE | Efficacy and safety of subcutaneous secukinumab for moderate to severe chronic plaque-type psoriasis for up to 1 year |
SCULPTURE | Efficacy and safety of subcutaneous secukinumab (AIN457) for moderate to severe chronic plaque-type psoriasis assessing different doses and dose regimens |
hs-CRP | high-sensitivity c-reactive protein |
UNCOVER-1,2 | A phase 3 study in participants with moderate to severe psoriasis |
UNCOVER-3 | A study in participants with moderate to severe psoriasis |
NF-kB | nuclear factor kappa light chain enhancer of activated B cells |
BSA | body surface area |
WHO | World Health Organisation |
References
- Parisi, R.; Symmons, D.; Griffiths, C.; Ashcroft, D.M. Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence. J. Investig. Dermatol. 2013, 133, 377–385. [Google Scholar] [CrossRef] [Green Version]
- Raychaudhuri, S.K.; Maverakis, E.; Raychaudhuri, S.P. Diagnosis and classification of psoriasis. Autoimmun. Rev. 2014, 13, 490–495. [Google Scholar] [CrossRef]
- Alinaghi, F.; Calov, M.; Kristensen, L.E.; Gladman, D.D.; Coates, L.C.; Jullien, D.; Gottlieb, A.B.; Gisondi, P.; Wu, J.J.; Thyssen, J.P.; et al. Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies. J. Am. Acad. Dermatol. 2019, 80, 251–265.e19. [Google Scholar] [CrossRef] [Green Version]
- McCormick, T.; Ayala-Fontanez, N.; Soler, D. Current knowledge on psoriasis and autoimmune diseases. Psoriasis Targets Ther. 2016, 6, 7–32. [Google Scholar] [CrossRef] [Green Version]
- Toussirot, Ã.; Aubin, F.; Dumoulin, G.; Toussirot, É.; Aubin, F. Relationships between Adipose Tissue and Psoriasis, with or without Arthritis. Front. Immunol. 2014, 5. [Google Scholar] [CrossRef] [Green Version]
- Mehta, N.N.; Yu, Y.; Pinnelas, R.; Krishnamoorthy, P.; Shin, D.B.; Troxel, A.; Gelfand, J.M. Attributable Risk Estimate of Severe Psoriasis on Major Cardiovascular Events. Am. J. Med. 2011, 124, 775.e1–775.e6. [Google Scholar] [CrossRef] [Green Version]
- Armstrong, A.W.; Harskamp, C.T.; Armstrong, E.J. Psoriasis and metabolic syndrome: A systematic review and meta-analysis of observational studies. J. Am. Acad. Dermatol. 2013, 68, 654–662. [Google Scholar] [CrossRef]
- Ferdinando, L.B.; Fukumoto, P.K.; Sanches, S.; Fabricio, L.H.Z.; Skare, T.L. Metabolic syndrome and psoriasis: A study in 97 patients. Revista Associação Médica Brasileira 2018, 64, 368–373. [Google Scholar] [CrossRef] [PubMed]
- Kyle, U.G.; Bosaeus, I.; De Lorenzo, A.D.; Deurenberg, P.; Elia, M.; Gómez, J.M. Bioelectrical impedance analysis--part I: Review of principles and methods. Clin Nutr. 2004, 23, 1226–1243. [Google Scholar] [CrossRef] [PubMed]
- Kumar, S.; Dutt, A.; Hemraj, S.; Bhat, S.; Manipadybhima, B. Phase Angle Measurement in Healthy Human Subjects through Bio-Impedance Analysis. Iran J. Basic Med. Sci. 2012, 15, 1180–1184. [Google Scholar]
- Buch, E.; Bradfield, J.; Larson, T.; Horwich, T. Effect of Bioimpedance Body Composition Analysis on Function of Implanted Cardiac Devices. Pacing Clin. Electrophysiol. 2012, 35, 681–684. [Google Scholar] [CrossRef]
- Llamas-Velasco, M.; de la Cueva, P.; Notario, J.; Martínez-Pilar, L.; Martorell, A.; Moreno-Ramírez, D. Moderate Psoriasis: A Pro-posed Definition. Actas Dermosifiliogr. 2017, 108, 911–917. [Google Scholar] [CrossRef]
- Jin, Y.; Zhang, F.; Yang, S.; Kong, Y.; Xiao, F.; Hou, Y.; Fan, X.; Zhang, X. Combined effects of HLA-Cw6, body mass index and waist–hip ratio on psoriasis vulgaris in Chinese Han population. J. Dermatol. Sci. 2008, 52, 123–129. [Google Scholar] [CrossRef] [PubMed]
- Tupikowska-Marzec, M.; Kolačkov, K.; Zdrojowy-Wełna, A.; Słoka, N.K.; Szepietowski, J.C.; Maj, J. The Influence of FTO Polymorphism rs9939609 on Obesity, Some Clinical Features, and Disturbance of Carbohydrate Metabolism in Patients with Psoriasis. BioMed. Res. Int. 2019, 2019, 1–5. [Google Scholar] [CrossRef] [Green Version]
- von Stebut, E.; Boehncke, W.H.; Ghoreschi, K.; Gori, T.; Kaya, Z.; Thaci, D. IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications. Front. Immunol. 2019, 10, 3096. [Google Scholar] [CrossRef] [Green Version]
- Tang, Y.; Bian, Z.; Zhao, L.; Liu, Y.; Liang, S.; Wang, Q.; Han, X.; Peng, Y.; Chen, X.; Shen, L.; et al. Interleukin-17 exacerbates hepatic steatosis and inflammation in non-alcoholic fatty liver disease. Clin. Exp. Immunol. 2011, 166, 281–290. [Google Scholar] [CrossRef]
- Chehimi, M.; Vidal, H.; Eljaafari, A. Pathogenic Role of IL-17-Producing Immune Cells in Obesity, and Related Inflammatory Diseases. J. Clin. Med. 2017, 6, 68. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gisondi, P.; Targher, G.; Zoppini, G.; Girolomoni, G. Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J. Hepatol. 2009, 51, 758–764. [Google Scholar] [CrossRef]
- Shinjo, T.; Iwashita, M.; Yamashita, A.; Sano, T.; Tsuruta, M.; Matsunaga, H.; Sanui, T.; Asano, T.; Nishimura, F. IL-17A synergistically enhances TNFα-induced IL-6 and CCL20 production in 3T3-L1 adipocytes. Biochem. Biophys. Res. Commun. 2016, 477, 241–246. [Google Scholar] [CrossRef] [PubMed]
- Shin, J.H.; Shin, D.W.; Noh, M. Interleukin-17A inhibits adipocyte differentiation in human mesenchymal stem cells and regulates pro-inflammatory responses in adipocytes. Biochem. Pharmacol. 2009, 77, 1835–1844. [Google Scholar] [CrossRef] [PubMed]
- Gerdes, S.; Pinter, A.; Biermann, M.; Papavassilis, C.; Reinhardt, M. Adiponectin levels in a large pooled plaque psoriasis study population. J. Dermatol. Treat. 2019, 31, 531–534. [Google Scholar] [CrossRef] [Green Version]
- Baran, A.; Flisiak, I.; Jaroszewicz, J.; Świderska, M. Effect of psoriasis activity on serum adiponectin and leptin levels. Adv. Dermatol. Allergol. 2015, 2, 101–106. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Paiva-Lopes, M.J.; Batuca, J.; Gouveia, S.; Alves, M.; Papoila, A.L.; Alves, J.D. Antibodies towards high-density lipoprotein components in patients with psoriasis. Arch. Dermatol. Res. 2019, 312, 93–102. [Google Scholar] [CrossRef]
- Tan, E.; Baker, C.; Foley, P. Weight gain and tumour necrosis factor-alpha inhibitors in patients with psoriasis. Australas. J. Dermatol. 2013, 54, 259–263. [Google Scholar] [CrossRef]
- Saraceno, R.; Schipani, C.; Mazzotta, A.; Esposito, M.; DiRenzo, L.; DeLorenzo, A.; Chimenti, S. Effect of anti-tumor necrosis factor-α therapies on body mass index in patients with psoriasis. Pharmacol. Res. 2008, 57, 290–295. [Google Scholar] [CrossRef]
- Montaudié, H.; Sbidian, E.; Paul, C.; Maza, A.; Gallini, A.; Aractingi, S.; Aubin, F.; Bachelez, H.; Cribier, B.; Joly, P.; et al. Methotrexate in psoriasis: A systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity. J. Eur. Acad. Dermatol. Venereol. 2011, 25, 12–18. [Google Scholar] [CrossRef] [PubMed]
- Gisondi, P.; Del Giglio, M.; Girolomoni, G. Considerations for Systemic Treatment of Psoriasis in Obese Patients. Am. J. Clin. Dermatol. 2016, 17, 609–615. [Google Scholar] [CrossRef] [PubMed]
- Gisondi, P.; Conti, A.; Galdo, G.; Piaserico, S.; de Simone, C.; Girolomoni, G. Ustekinumab does not increase body mass index in patients with chronic plaque psoriasis: A prospective cohort study. Br. J. Dermatol. 2013, 168, 1124–1127. [Google Scholar] [CrossRef] [PubMed]
- Gordon, K.; Blauvelt, A.; Foley, P.; Song, M.; Wasfi, Y.; Randazzo, B.; Shen, Y.; You, Y.; Griffiths, C. Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: A pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies. Br. J. Dermatol. 2017, 178, 132–139. [Google Scholar] [CrossRef] [Green Version]
- Strober, B.; Menter, A.; Leonardi, C.; Gordon, K.; Lambert, J.; Puig, L.; Photowala, H.; Longcore, M.; Zhan, T.; Foley, P. Efficacy of risankizumab in patients with moderate-to-severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: An integrated analysis of the phase III UltIMMa-1 and UltIMMa-2 studies. J. Eur. Acad. Dermatol. Venereol. 2020, 34, 2830–2838. [Google Scholar] [CrossRef]
- Gerdes, S.; Pinter, A.; Papavassilis, C.; Reinhardt, M. Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients. J. Eur. Acad. Dermatol. Venereol. 2019, 34, 533–541. [Google Scholar] [CrossRef] [Green Version]
- Gisondi, P.; Bellinato, F.; Bruni, M.; De Angelis, G.; Girolomoni, G. Methotrexate vs secukinumab safety in psoriasis patients with metabolic syndrome. Dermatol. Ther. 2020, 33. [Google Scholar] [CrossRef] [PubMed]
- Wang, H.N.; Huang, Y.H. Changes in metabolic parameters in psoriatic patients treated with secukinumab. Ther. Adv. Chronic Dis. 2020, 11. [Google Scholar] [CrossRef] [PubMed]
- Egeberg, A.; Wu, J.J.; Korman, N.; Solomon, J.A.; Goldblum, O.; Zhao, F.; Mallbris, L. Ixekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate-to-severe plaque psoriasis: Results from UNCOVER-1, UNCOVER-2, and UNCOVER-3. J. Am. Acad. Dermatol. 2018, 79, 104–109. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Huang, L.-H.; Zinselmeyer, B.H.; Chang, C.-H.; Saunders, B.T.; Elvington, A.; Baba, O.; Broekelmann, T.J.; Qi, L.; Rueve, J.S.; Swartz, M.A.; et al. Interleukin-17 Drives Interstitial Entrapment of Tissue Lipoproteins in Experimental Psoriasis. Cell Metab. 2019, 29, 475–487. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Al-Harbi, N.O.; Nadeem, A.; Al-Harbi, M.M.; Zoheir, K.M.; Ansari, M.A.; El-Sherbeeny, A.M.; Alanazi, K.M.; Alotaibi, M.R.; Ahmad, S.F. Psoriatic inflammation causes hepatic inflammation with concomitant dysregulation in hepatic metabolism via IL-17A/IL-17 receptor signaling in a murine model. Immunobiology. 2017, 222, 128–136. [Google Scholar] [CrossRef]
- Langan, S.M.; Seminara, N.M.; Shin, D.B.; Troxel, A.; Kimmel, S.E.; Mehta, N.N.; Margolis, D.J.; Gelfand, J.M. Prevalence of Metabolic Syndrome in Patients with Psoriasis: A Population-Based Study in the United Kingdom. J. Investig. Dermatol. 2012, 132, 556–562. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Choi, D.; Choi, S.; Son, J.S.; Oh, S.W.; Park, S.M. Impact of Discrepancies in General and Abdominal Obesity on Major Adverse Cardiac Events. J. Am. Hear. Assoc. 2019, 8, e013471. [Google Scholar] [CrossRef] [PubMed]
- Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. World Health Organ Tech. Rep. Ser. 1995, 854, 1–452. [Google Scholar]
Patients’ Comorbidities | N (%) or Median (IQR) |
---|---|
Total sample | 35 (100) |
Sex | |
Women | 14 (40) |
Men | 21 (60) |
Age (years) | 49 (37–62) |
Disease duration (years) | 22 (13–27) |
BMI (kg/m2) | 32.8 (27.14–37.97) |
Psoriatic arthritis | 18 (51.42) |
Treatments | |
Bio-naive | 6 (17.14) |
Secukinumab | 22 (62.86) |
Ixekizumab | 13 (37.14) |
Characteristics | Baseline, Median (IQR) | 6-Month Follow-Up, Median (IQR) | p-Value (Wilcoxon Signed-Rank Test) |
---|---|---|---|
Clinical Characteristics | |||
PASI (0–72) | 18.00 (14–30) | 0.0 (0–4) | <0.001 |
DLQI (0–30) | 17.00 (10–27) | 0.0 (0–1) | <0.001 |
Laboratory Characteristics | |||
CRP (mg/L) | 6.60 (3.20–15.00) | 4.00 (2.10–5.60) | <0.001 |
ESR (mm/h) | 17.00 (5–37) | 7.00 (4–22) | 0.004 |
HDL-cholesterol (mmol/L) | 1.31 (1.16–1.53) | 1.40 (1.25–1.60) | 0.022 |
LDL-cholesterol (mmol/L) | 3.69 (2.75–4.24) | 3.19 (2.27–3.83) | 0.004 |
Total cholesterol (mmol/L) | 5.40 (4.40–6.50) | 5.26 (4.30–6.20) | 0.161 |
Triglyceride (mmol/L) | 1.52 (1.11–2.00) | 1.50 (1.10–2.38) | 0.116 |
Fasting glucose (mmol/L) | 5.60 (4.80–6.30) | 5.22 (4.70–6.40) | 0.640 |
AST (U/L) | 24.00 (19–35) | 24.00 (18–28) | 0.207 |
ALT (U/L) | 24.00 (18–43) | 24.00 (17–34) | 0.011 |
GGT (U/L) | 31.00 (21–65) | 28.00 (20–60) | 0.120 |
Characteristics | Baseline Median (IQR) | 6-Month Follow-Up Median (IQR) | p-Value (Wilcoxon Signed-Rank Test) |
---|---|---|---|
Body weight (kg) | 97.00 (75.70–111.00) | 96.70 (77.40–112.20) | 0.269 |
BMI (kg/m2) | 32.80 (27.14–37.97) | 32.80 (27.21–38.18) | 0.439 |
Fat-free mass (kg) | 55.20 (49.60–69.70) | 54.60 (48.6–70.60) | 0.895 |
FFMI (kg/m2) | 20.17 (18.76–21.88) | 20.00 (18.32–22.46) | 0.631 |
TBW (L) | 40.60 (36.40–51.10) | 40.60 (36.20–51.80) | 1.000 |
Protein (kg) | 10.80 (9.70–13.70) | 10.70 (9.40–14.00) | 0.741 |
Minerals (kg) | 3.67 (3.09–4.71) | 3.61 (3.25–4.75) | 0.405 |
Body fat mass (kg) | 33.30 (23.10–47.20) | 33.30 (24.20–46.70) | 0.548 |
BFMI (kg/m2) | 10.99 (7.87–17.22) | 11.15 (8.08–17.86) | 0.605 |
Body fat percent (%) | 37.10 (28.90–47.60) | 36.90 (29.00–47.30) | 0.885 |
Skeletal muscle mass (kg) | 30.80 (27.30–39.10) | 30.40 (26.40–40.50) | 0.727 |
SMMI (kg/m2) | 11.21 (10.30–12.11) | 11.09 (10.15–12.61) | 0.556 |
ECW ratio | 0.38 (0.38–0.39) | 0.38 (0.38–0.39) | 0.984 |
Phase Angle (◦) | 5.60 (5.00–6.00) | 5.60 (5.30–6.10) | 0.214 |
Visceral fat area (cm2) | 165.50 (115.20–229.20) | 164.20 (110.70–220.80) | 0.524 |
Body cell mass (kg) | 36.0 (32.20–45.20) | 35.60 (31.20–46.60) | 0.741 |
Bone mineral content (kg) | 3.06 (2.48–3.86) | 2.95 (2.583.91) | 0.561 |
ECW (L) | 15.70 (13.90–19.80) | 15.70 (13.90–19.50) | 0.698 |
ICW (L) | 25.10 (22.50–31.50) | 24.90 (21.80–32.60) | 0.709 |
InBody Score | 65.0 (53.0–72.0) | 65.0 (54.0–73.0) | 0.777 |
PASI (0–72) Change (N = 35) | CRP (mg/L) Change (N = 35) | ESR (mm/h) Change (N = 35) | HDL-cholesterol (mmol/L) Change (N = 35) | LDL-cholesterol (mmol/L) Change (N = 33) | |
---|---|---|---|---|---|
PASI (0–72) Change (N = 35) | - | 0.133 | 0.006 | −0.031 | 0.046 |
CRP (mg/L) Change(N = 35) | - | - | 0.424 * | −0.210 | 0.054 |
ESR (mm/h) Change(N = 35) | - | - | - | −0.001 | −0.007 |
HDL-cholesterol (mmol/L) Change (N = 35) | - | - | - | - | −0.180 |
LDL-cholesterol (mmol/L) Change (N = 33) | - | - | - | - | - |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Piros, É.A.; Szabó, Á.; Rencz, F.; Brodszky, V.; Wikonkál, N.; Miheller, P.; Horváth, M.; Holló, P. Anti-Interleukin-17 Therapy of Severe Psoriatic Patients Results in an Improvement of Serum Lipid and Inflammatory Parameters’ Levels, but Has No Effect on Body Composition Parameters. Life 2021, 11, 535. https://doi.org/10.3390/life11060535
Piros ÉA, Szabó Á, Rencz F, Brodszky V, Wikonkál N, Miheller P, Horváth M, Holló P. Anti-Interleukin-17 Therapy of Severe Psoriatic Patients Results in an Improvement of Serum Lipid and Inflammatory Parameters’ Levels, but Has No Effect on Body Composition Parameters. Life. 2021; 11(6):535. https://doi.org/10.3390/life11060535
Chicago/Turabian StylePiros, Éva Anna, Ákos Szabó, Fanni Rencz, Valentin Brodszky, Norbert Wikonkál, Pál Miheller, Miklós Horváth, and Péter Holló. 2021. "Anti-Interleukin-17 Therapy of Severe Psoriatic Patients Results in an Improvement of Serum Lipid and Inflammatory Parameters’ Levels, but Has No Effect on Body Composition Parameters" Life 11, no. 6: 535. https://doi.org/10.3390/life11060535
APA StylePiros, É. A., Szabó, Á., Rencz, F., Brodszky, V., Wikonkál, N., Miheller, P., Horváth, M., & Holló, P. (2021). Anti-Interleukin-17 Therapy of Severe Psoriatic Patients Results in an Improvement of Serum Lipid and Inflammatory Parameters’ Levels, but Has No Effect on Body Composition Parameters. Life, 11(6), 535. https://doi.org/10.3390/life11060535